{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:50:17Z","timestamp":1792108217710,"version":"4.4.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10928-026-10053-8","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:15:21Z","timestamp":1785352521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strategies for pediatric dose derivation from population pharmacokinetic models"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4686-976X","authenticated-orcid":false,"given":"Andreas","family":"Krause","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6904-5569","authenticated-orcid":false,"given":"G\u00e9raldine","family":"Celli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"10053_CR1","unstructured":"FDA (2013) Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended. Initial Pediatric Study Plans. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pediatric-study-plans-content-and-process-submitting-initial-pediatric-study-plans-and-amended"},{"key":"10053_CR2","unstructured":"European Union (2006) Regulation (EC) 1901\/2006 of the European parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) 726\/2004. http:\/\/data.europa.eu\/eli\/reg\/2006\/1901\/2019-01-28"},{"key":"10053_CR3","unstructured":"PMDA (2025) Initiatives to Promote Pediatric Drug Development. https:\/\/www.pmda.go.jp\/files\/000274940.pdf. Accessed 9 Feb 2026"},{"key":"10053_CR4","unstructured":"Sakiyama M (2023) Pediatric Drug Development in Japan. https:\/\/www.pmda.go.jp\/files\/000263353.pdf. Accessed 9 Feb 2026"},{"key":"10053_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1460-9592.2011.03523.x","volume":"21","author":"E Manolis","year":"2011","unstructured":"Manolis E, Osman TE, Herold R et al (2011) Role of modeling and simulation in pediatric investigation plans. Paediatr Anaesth 21:214\u2013221. https:\/\/doi.org\/10.1111\/j.1460-9592.2011.03523.x","journal-title":"Paediatr Anaesth"},{"key":"10053_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","volume":"45","author":"IH Bartelink","year":"2006","unstructured":"Bartelink IH, Rademaker CMA, Schobben AFAM, Van Den Anker JN (2006) Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45:1077\u20131097. https:\/\/doi.org\/10.2165\/00003088-200645110-00003","journal-title":"Clin Pharmacokinet"},{"key":"10053_CR7","doi-asserted-by":"publisher","first-page":"e1242","DOI":"10.1542\/peds.2010-3487","volume":"128","author":"J Dunne","year":"2011","unstructured":"Dunne J, Rodriguez WJ, Murphy MD et al (2011) Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics 128:e1242\u2013e1249. https:\/\/doi.org\/10.1542\/peds.2010-3487","journal-title":"Pediatrics"},{"key":"10053_CR8","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1002\/jcph.1834","volume":"61","author":"TN Johnson","year":"2021","unstructured":"Johnson TN, Ke AB (2021) Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line? J Clin Pharmacol 61:S83\u2013S93. https:\/\/doi.org\/10.1002\/jcph.1834","journal-title":"J Clin Pharmacol"},{"key":"10053_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/psp4.12038","volume":"4","author":"C Stockmann","year":"2015","unstructured":"Stockmann C, Barrett J, Roberts J, Sherwin C (2015) Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. CPT Pharmacometrics Syst Pharmacol 4:630\u2013640. https:\/\/doi.org\/10.1002\/psp4.12038","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10053_CR10","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jcph.555","volume":"55","author":"TS Samant","year":"2015","unstructured":"Samant TS, Mangal N, Lukacova V, Schmidt S (2015) Quantitative clinical pharmacology for size and age scaling in pediatric drug development: A systematic review. J Clin Pharmacol 55:1207\u20131217. https:\/\/doi.org\/10.1002\/jcph.555","journal-title":"J Clin Pharmacol"},{"key":"10053_CR11","unstructured":"EMA (2018) Extrapolation of efficacy and safety in paediatric medicine development - Scientific guideline. https:\/\/www.ema.europa.eu\/en\/extrapolation-efficacy-safety-paediatric-medicine-development-scientific-guideline. Accessed 1 Jul 2026"},{"key":"10053_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40262-014-0134-5","volume":"53","author":"I Mahmood","year":"2014","unstructured":"Mahmood I (2014) Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings. Clin Pharmacokinet 53:327\u2013346. https:\/\/doi.org\/10.1007\/s40262-014-0134-5","journal-title":"Clin Pharmacokinet"},{"key":"10053_CR13","unstructured":"FDA (2024) A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy. https:\/\/clinicaltrials.gov\/study\/NCT02085148. Accessed 16 Feb 2026"},{"key":"10053_CR14","unstructured":"FDA (2023) A Phase 1\/2\/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children. https:\/\/clinicaltrials.gov\/study\/NCT04816643. Accessed 16 Feb 2026"},{"key":"10053_CR15","unstructured":"FDA (2026) Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to <\u200918 Years With Insomnia Disorder. https:\/\/clinicaltrials.gov\/study\/NCT05423717. Accessed 15 Feb 2026"},{"key":"10053_CR16","unstructured":"FDA (2023) Pediatric Drug Development: Regulatory Considerations. https:\/\/www.fda.gov\/media\/168201\/download. Accessed 30 Jun 2026"},{"key":"10053_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/pharmaceutics2040364","volume":"2","author":"J Zisowsky","year":"2010","unstructured":"Zisowsky J, Krause A, Dingemanse J (2010) Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics 2:364\u2013388. https:\/\/doi.org\/10.3390\/pharmaceutics2040364","journal-title":"Pharmaceutics"},{"key":"10053_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17425255.2021.2027907","volume":"18","author":"A van Rongen","year":"2022","unstructured":"van Rongen A, Krekels EH, Calvier EA et al (2022) An update on the use of allometric and other scaling methods to scale drug clearance in children: towards decision tables. Expert Opin Drug Metab Toxicol 18:99\u2013113. https:\/\/doi.org\/10.1080\/17425255.2021.2027907","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10053_CR19","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.ejps.2017.05.056","volume":"109","author":"NHG Holford","year":"2017","unstructured":"Holford NHG, Anderson BJ (2017) Allometric size: The scientific theory and extension to normal fat mass. Eur J Pharm Sci 109:S59\u2013S64. https:\/\/doi.org\/10.1016\/j.ejps.2017.05.056","journal-title":"Eur J Pharm Sci"},{"key":"10053_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG (2008) Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10053_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.3289","volume":"116","author":"K Rowland Yeo","year":"2024","unstructured":"Rowland Yeo K, Gil Berglund E, Chen Y (2024) Dose Optimization Informed by PBPK Modeling: State-of\u2010the Art and Future. Clin Pharmacol Ther 116:563\u2013576. https:\/\/doi.org\/10.1002\/cpt.3289","journal-title":"Clin Pharmacol Ther"},{"key":"10053_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2014.45","volume":"3","author":"AR Maharaj","year":"2014","unstructured":"Maharaj AR, Edginton AN (2014) Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development. CPT Pharmacometrics Syst Pharmacol 3:1\u201313. https:\/\/doi.org\/10.1038\/psp.2014.45","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10053_CR23","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1038\/psp.2013.41","volume":"2","author":"H Jones","year":"2013","unstructured":"Jones H, Rowland-Yeo K (2013) Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet Syst Pharmacol 2:e63. https:\/\/doi.org\/10.1038\/psp.2013.41","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10053_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/psp4.12764","volume":"11","author":"TN Johnson","year":"2022","unstructured":"Johnson TN, Small BG, Rowland Yeo K (2022) Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations. CPT Pharmacometrics Syst Pharmacol 11:373\u2013383","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10053_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70141","author":"JWT Yates","year":"2026","unstructured":"Yates JWT, Zientek M, Taskar KS et al (2026) Physiologically-based pharmacokinetic modeling to support pediatric clinical development: an IQ working group perspective on the current status and challenges. CPT Pharmacomet Syst Pharmacol. https:\/\/doi.org\/10.1002\/psp4.70141","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10053_CR26","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1002\/jcph.1853","volume":"61","author":"FG Green","year":"2021","unstructured":"Green FG, Park K, Burckart GJ (2021) Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020. J Clin Pharmacol 61:S28\u2013S35. https:\/\/doi.org\/10.1002\/jcph.1853","journal-title":"J Clin Pharmacol"},{"key":"10053_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16395","author":"CWM Simons","year":"2025","unstructured":"Simons CWM, Maton LCH, van Dartel M et al (2025) A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.16395","journal-title":"Br J Clin Pharmacol"},{"key":"10053_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70155","author":"A Gupta","year":"2026","unstructured":"Gupta A, Pouliquen IJ, Phipatanakul W et al (2026) Development of pediatric dosing for mepolizumab in severe asthma based on extrapolation of data from adult patients and a phase II open-label pediatric trial. J Clin Pharmacol. https:\/\/doi.org\/10.1002\/jcph.70155","journal-title":"J Clin Pharmacol"},{"key":"10053_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2125.2006.02622.x","volume":"61","author":"I Mahmood","year":"2006","unstructured":"Mahmood I (2006) Prediction of drug clearance in children from adults: A comparison of several allometric methods. Br J Clin Pharmacol 61:545\u2013557. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02622.x","journal-title":"Br J Clin Pharmacol"},{"key":"10053_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0022-3476(78)80601-5","volume":"93","author":"GB Haycock","year":"1978","unstructured":"Haycock GB, Schwartz GJ, Wisotsky DH (1978) Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adults. J Pediatr 93:62\u201366. https:\/\/doi.org\/10.1016\/S0022-3476(78)80601-5","journal-title":"J Pediatr"},{"key":"10053_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/jcp.19.4.389","volume":"19","author":"R Hume","year":"1966","unstructured":"Hume R (1966) Prediction of lean body mass from height and weight. J Clin Pathol 19:389\u2013391. https:\/\/doi.org\/10.1136\/jcp.19.4.389","journal-title":"J Clin Pathol"},{"key":"10053_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.ejcn.1601254","volume":"55","author":"P Deurenberg","year":"2001","unstructured":"Deurenberg P, Andreoli A, Borg P et al (2001) The validity of predicted body fat percentage from body mass index and from impedance in samples of five European populations. Eur J Clin Nutr 55:973\u2013979. https:\/\/doi.org\/10.1038\/sj.ejcn.1601254","journal-title":"Eur J Clin Nutr"},{"key":"10053_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/psp4.12877","volume":"12","author":"A Krause","year":"2023","unstructured":"Krause A, Lott D, Brussee JM et al (2023) Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist. CPT Pharmacometrics Syst Pharmacol 12:74\u201386. https:\/\/doi.org\/10.1002\/psp4.12877","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10053_CR34","unstructured":"WHO (2020) Child growth standards. https:\/\/www.who.int\/toolkits\/child-growth-standards\/standards\/weight-for-age. Accessed 16 Jun 2026"},{"key":"10053_CR35","unstructured":"Health Policy Team at the Royal College of Paediatrics and Child Health UK-WHO growth charts\u2009\u2013\u20092\u201318 years. https:\/\/www.rcpch.ac.uk\/resources\/uk-who-growth-charts-2-18-years. Accessed 16 Jun 2026"},{"key":"10053_CR36","unstructured":"FDA (2002) Humira (adalimumab) United States Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s410lbl.pdf. Accessed 19 Jan 2026"},{"key":"10053_CR37","unstructured":"FDA (2023) Diastat C-IV (diazepam rectal gel) United States prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/020648s023lbl.pdf. Accessed 19 Jan 2026"},{"key":"10053_CR38","unstructured":"EMA (2016) Buccolam (midazolam buccal) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/buccolam-epar-product-information_en.pdf. Accessed 19 Jan 2026"},{"key":"10053_CR39","unstructured":"FDA (2019) Bosentan United States Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021290s039,209279s005lbl.pdf. Accessed 19 Jan 2026"},{"key":"10053_CR40","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/psp4.12286","volume":"7","author":"A K\u00fcmmel","year":"2018","unstructured":"K\u00fcmmel A, Bonate PL, Dingemanse J, Krause A (2018) Confidence and prediction intervals for pharmacometric models. CPT Pharmacomet Syst Pharmacol 7:360\u2013373. https:\/\/doi.org\/10.1002\/psp4.12286","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10053_CR41","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1002\/sim.8386","volume":"38","author":"BG Francq","year":"2019","unstructured":"Francq BG, Lin D, Hoyer W (2019) Confidence, prediction, and tolerance in linear mixed models. Stat Med 38:5603\u20135622. https:\/\/doi.org\/10.1002\/sim.8386","journal-title":"Stat Med"},{"key":"10053_CR42","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1172\/JCI104839","volume":"42","author":"RA O\u2019Reilly","year":"1963","unstructured":"O\u2019Reilly RA, Aggeler PM, Leong LS (1963) Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man. J Clin Invest 42:1542\u20131551. https:\/\/doi.org\/10.1172\/JCI104839","journal-title":"J Clin Invest"},{"key":"10053_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1161\/01.CIR.38.1.169","volume":"38","author":"RA O\u2019Reilly","year":"1968","unstructured":"O\u2019Reilly RA, Aggeler PM (1968) Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose. Circulation 38:169\u2013177. https:\/\/doi.org\/10.1161\/01.CIR.38.1.169","journal-title":"Circulation"},{"key":"10053_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-024-01444-6","volume":"64","author":"DW van Valkengoed","year":"2025","unstructured":"van Valkengoed DW, Krekels EHJ, Knibbe CAJ (2025) All You Need to Know About Allometric Scaling: An Integrative Review on the Theoretical Basis, Empirical Evidence, and Application in Human Pharmacology. Clin Pharmacokinet 64:173\u2013192. https:\/\/doi.org\/10.1007\/s40262-024-01444-6","journal-title":"Clin Pharmacokinet"},{"key":"10053_CR45","unstructured":"Simulations Plus Inc (2020) Log-likelihood estimation. https:\/\/monolixsuite.slp-software.com\/monolix\/2024R1\/likelihood. Accessed 19 Jan 2026"},{"key":"10053_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/jcph.1701","volume":"61","author":"A Krause","year":"2021","unstructured":"Krause A, Lott D, Dingemanse J (2021) Estimation of attainment of steady-state conditions for compounds with a long half-life. J Clin Pharmacol 61:82\u201389. https:\/\/doi.org\/10.1002\/jcph.1701","journal-title":"J Clin Pharmacol"},{"key":"10053_CR47","unstructured":"R Development Core Team R A language and environment for statistical computing"},{"key":"10053_CR48","unstructured":"Simulations Plus Inc (2025) Monolix documentation. https:\/\/monolixsuite.slp-software.com\/monolix\/2024R1\/. Accessed 24 Feb 2026"},{"key":"10053_CR49","unstructured":"Simulations Plus Inc (2025) Simulx documentation. https:\/\/monolixsuite.slp-software.com\/simulx\/2024R1\/. Accessed 15 Jan 2025"},{"key":"10053_CR50","unstructured":"Simulations Plus Inc (2025) MonolixSuite in R. https:\/\/monolixsuite.slp-software.com\/r-functions\/2024R1\/. Accessed 19 Jan 2026"},{"key":"10053_CR51","unstructured":"Simulations Plus Inc (2025) R Package RsSimulx. https:\/\/monolixsuite.slp-software.com\/r-functions\/2024R1\/package-rssimulx. Accessed 19 Jan 2026"},{"key":"10053_CR52","unstructured":"Wickham H, Navarro D, Pedersen TL (2023) ggplot2: Elegant Graphics for Date Science. https:\/\/ggplot2-book.org\/. Accessed 19 Jul 2023"},{"key":"10053_CR53","unstructured":"Simulations Plus Inc MonolixSuite download page. https:\/\/monolixsuite.slp-software.com\/getting-started\/2024R1\/download-menu. Accessed 25 Feb 2025"},{"key":"10053_CR54","unstructured":"ICH (2001) ICH E11 Guidance for industry: Clinical Investigation of Medicinal Products in the Paediatric Population, Step 5. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002926.pdf. Accessed 30 Jun 2026"},{"key":"10053_CR55","unstructured":"ICH (2018) ICH harmonised guideline E11 (R1): Addendum to ICH E11: Clinical investigation of medicinal producs in the pediatric population"},{"key":"10053_CR56","unstructured":"ICH (2022) ICH harmonised guideline E11A pediatric extrapolation (draft version)"},{"key":"10053_CR57","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/jcph.744","volume":"56","author":"Y Mulugeta","year":"2016","unstructured":"Mulugeta Y, Barrett JS, Nelson R et al (2016) Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development. J Clin Pharmacol 56:1326\u20131334. https:\/\/doi.org\/10.1002\/jcph.744","journal-title":"J Clin Pharmacol"},{"key":"10053_CR58","unstructured":"FDA (2022) General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/general-clinical-pharmacology-considerations-pediatric-studies-drugs-including-biological-products"},{"key":"10053_CR59","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bcp.13160","volume":"83","author":"E Germovsek","year":"2017","unstructured":"Germovsek E, Barker CIS, Sharland M, Standing JF (2017) Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful? Br J Clin Pharmacol 83:777\u2013790. https:\/\/doi.org\/10.1111\/bcp.13160","journal-title":"Br J Clin Pharmacol"},{"key":"10053_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/psp4.12366","volume":"8","author":"EHJ Krekels","year":"2019","unstructured":"Krekels EHJ, Calvier EAM, van der Graaf PH, Knibbe CAJ (2019) Children are not small adults, but can we treat them as such? CPT Pharmacomet Syst Pharmacol 8:34\u201338. https:\/\/doi.org\/10.1002\/psp4.12366","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10053_CR61","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40262-018-0652-7","volume":"58","author":"SC Goulooze","year":"2019","unstructured":"Goulooze SC, V\u00f6ller S, V\u00e4litalo PAJ et al (2019) The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models. Clin Pharmacokinet 58:131\u2013138. https:\/\/doi.org\/10.1007\/s40262-018-0652-7","journal-title":"Clin Pharmacokinet"},{"key":"10053_CR62","doi-asserted-by":"crossref","unstructured":"Santulli AR (2025) SimKid: Simulate Virtual Pediatrics using Anthropometric Growth Charts (R package). https:\/\/cran.r-project.org\/web\/packages\/SimKid\/citation.html. Accessed 14 Feb 2026","DOI":"10.32614\/CRAN.package.SimKid"},{"key":"10053_CR63","unstructured":"ter Heine R (2026) Copulapop (R package). https:\/\/github.com\/robterheine\/copulapop. Accessed 14 Feb 2026"},{"key":"10053_CR64","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT (2006) Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children. Clin Pharmacokinet 45:931\u2013956. https:\/\/doi.org\/10.2165\/00003088-200645090-00005","journal-title":"Clin Pharmacokinet"},{"key":"10053_CR65","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/jcph.488","volume":"55","author":"F Foissac","year":"2015","unstructured":"Foissac F, Bouazza N, Valade E et al (2015) Prediction of drug clearance in children. J Clin Pharmacol 55:739\u2013747. https:\/\/doi.org\/10.1002\/jcph.488","journal-title":"J Clin Pharmacol"},{"key":"10053_CR66","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/psp4.12273","volume":"7","author":"EAM Calvier","year":"2018","unstructured":"Calvier EAM, Krekels EHJ, Yu H et al (2018) Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. CPT Pharmacometrics Syst Pharmacol 7:175\u2013185. https:\/\/doi.org\/10.1002\/psp4.12273","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10053_CR67","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40272-016-0206-0","volume":"19","author":"J Zisowsky","year":"2017","unstructured":"Zisowsky J, G\u00e9hin M, Kusic-Pajic A et al (2017) Pediatric Development of Bosentan Facilitated by Modeling and Simulation. Pediatr Drugs 19:121\u2013130. https:\/\/doi.org\/10.1007\/s40272-016-0206-0","journal-title":"Pediatr Drugs"},{"key":"10053_CR68","unstructured":"FDA (2011) Warfarin prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/009218s107lbl.pdf"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10053-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:21:44Z","timestamp":1792106504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10053-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10053"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10053-8","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Microsoft Copilot was used in copyediting selected parts of the manuscript.","order":1,"name":"Ethics","label":"Use of artificial intelligence","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GC is a current and AK a former employee of Simulations Plus, Inc., the company developing and commercializing the MonolixSuite software.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"46"}}